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ABSTRACT
Activation of c-MET through hepatocyte growth factor (HGF) increases 
tumorigenesis, induces resistance, and is associated with poor prognosis in various 
solid tumors. However, the clinical value of serum HGF (sHGF) in patients with 
advanced non-small cell lung cancer (NSCLC), especially those receiving cytotoxic 
chemotherapy, remains unknown. Here, we show that sHGF may be useful to predict 
tumor response and progression-free survival (PFS) in patients with advanced NSCLC. 
A total of 81 patients with NSCLC were investigated. sHGF levels were evaluated using 
ELISA at 4 time-points: at pre-treatment, at response-evaluation (1–2 months after 
treatment initiation), at the best tumor response, and at disease progression. As a 
control biomarker, CEA was also evaluated in lung adenocarcinoma. Positive-sHGF 
at response-evaluation predicted poor PFS compared with Negative-sHGF in both 
first-line (median, 153.5 vs. 288.0; P < 0.05) and second-line treatment (87.0 vs. 
219.5; P = 0.01). In 55 patients that received cytotoxic chemotherapy, multiple Cox 
proportional hazards models showed significant independent associations between 
poor PFS and Positive-sHGF at response-evaluation (hazard ratio, 4.24; 95% CI, 2.05 
to 9.46; P < 0.01). Lung adenocarcinoma subgroup analysis showed that in patients 
receiving second cytotoxic chemotherapy, there were no significant differences in 
PFS between patients with low-CEA compared with those with high-CEA, but Positive-
sHGF at pre-treatment or at response-evaluation predicted poor PFS (35.0 vs. 132.0; 
P < 0.01, 50.0 vs. 215.0; P < 0.01, respectively). These findings give a rationale for 
future research investigating the merit of sHGF as a potential clinical biomarker to 
evaluate HGF/c-MET activity, which would be useful to indicate administration of 
c-MET inhibitors.
INTRODUCTION
Hepatocyte growth factor (HGF) is a soluble ligand 
of the c-MET tyrosine kinase receptor. Activation of 
the HGF/c-MET signaling pathway contributes to the 
promotion of tumor cell motility, scattering, invasion, 
and metastasis, suggesting it to be a negative prognostic 
indicator for cell survival and recurrence in some solid 
tumors including lung cancer [1, 2].
Overexpression of both HGF and/or its receptor 
c-MET have been reported in non-small cell lung 
cancer (NSCLC) cell lines and patients [3–8]. Increased 
expression of HGF is associated with acquired resistance 
to EGFR-TKIs by bypass signaling via MAPK/ERK and 
PI3K/AKT pathways and by promoting clonal selection 
of subpopulations by c-MET amplification [9, 10]. 
Preclinical findings also showed that the aberrant c-MET/
HGF pathway plays an important role in cytotoxic 
                                                               Research Paper
Oncotarget71806www.impactjournals.com/oncotarget
chemotherapy (CC) resistance in small-cell lung cancer 
(SCLC) [11].
Activation of the HGF/c-MET pathway has been 
evaluated using serum or plasma HGF, because HGF is 
expelled from tumor cells to the extracellular matrix and 
blood plasma by a paracrine mechanism [12]. Increased 
serum HGF (sHGF) has been reported to be a negative 
prognostic marker in various malignancies including 
colorectal cancer, gastric cancer [13–15], prostate cancer 
[16], ovarian cancer [17], breast cancer [18, 19], glioma[20], 
melanoma [21], and multiple myeloma [22, 23]. Recently, 
a Spanish group reported that high sHGF in patients with 
SCLC predicts poor outcome and epithelial-mesenchymal 
transition (EMT) change in the tumor [24, 25].
We previously reported that lung cancer cell 
lines had increased expression of c-MET due to gene 
amplification-induced cytotoxic drug resistance, and that 
resistant cells paracrine HGF and promote its resistance 
[26]. However, the clinical significance of sHGF in 
patients with advanced or recurrent NSCLC, especially in 
patients treated with CC, is yet to be identified. Here we 
report a retrospective cohort study suggesting that sHGF 
concentration is a potential predictive biomarker for poor 
clinical outcome in patients with NSCLC. 
RESULTS
sHGF in NSCLC patients and healthy controls 
A total of 81 patients were investigated; 53 patients 
received first-line and 48 patients received second-line 
therapy. The median sHGF value at pre-treatment of first-
line and second-line therapy were 0.41 and 0.33 ng/ml, 
respectively (Figure 1A). Then, thirty healthy controls 
were collected and matched to the current study population 
by smoking status, gender, and age (Table 1). Of the 30, 
two healthy controls (6.7%) had Positive-sHGF. The 
value was significantly higher in patients with NSCLC 
compared with healthy controls (P < 0.01, using the 
Mann-Whitney U test, Figure 1A). In 28 healthy controls 
with Negative-sHGF, the values were extrapolated using 
a calibration curve to consider the rationale of the cutoff 
value (0.3 ng/ml). The median value was 0.22 ng/ml and 
the mean ± S.D. was 0.22 ± 0.05 ng/ml (Figure 1A).
sHGF trends in patients with NSCLC
In 53 patients receiving first-line therapy, Positive-
sHGF was observed in 71.1%, 40.6%, 6.3%, and 54.8% 
at pre-treatment, response-evaluation, best response, and 
disease progression, respectively. sHGF concentration 
was significantly decreased at response-evaluation 
(median value (MV): under the limit of detection (LOD); 
P < 0.01) or at best response (MV: under the LOD; 
P < 0.01) compared with at pre-treatment (MV: 0.41 ng/
ml). sHGF values at disease progression (MV: 0.33 ng/ml) 
were significantly increased compared with those at best 
response (P = 0.01) (Figure 1B). In 48 patients receiving 
second-line therapy, a similar trend was observed 
(Figure 1C). sHGF was decreased at best response 
compared with pre-treatment (MV: under the LOD vs. 
0.33; P = 0.02) and increased at disease progression 
compared with best response (MV: 0.36 vs. under the 
LOD; P < 0.01). Then, sHGF kinetics in patients whose 
best responses were PD was investigated. sHGF values 
at response-evaluation (when PD) were not significantly 
increased compared with pre-treatment, but the values 
before next treatment tended to be increased (P = 0.06, 
Supplementary Figure 2A–2C).
sHGF value was potentially associated with the 
best response
Trends of sHGF value according to the best 
response were presented in Figure 2A and 2B. sHGF 
level at response-evaluation was significantly higher in 
patients whose best responses were PD compared with 
those whose diseases were controlled (CR, PR, or SD) 
(Figure 2C and 2D). sHGF values in patients with PR/CR 
tended to be lower compared with patients with SD, but a 
significant difference was not detected (Figure 2A and 2B).
Positive-sHGF at response-evaluation predicted 
poor PFS in NSCLC
sHGF values at response-evaluation were obtained 
in 41 and 40 patients receiving first-line and second-line 
treatments, respectively (Table 2). PFS in Positive-sHGF 
patients was significantly shorter compared with Negative-
sHGF patients in both first-line (Median PFS (days): 153.5 
vs. 288.0; P = 0.047) and second-line (87.0 vs. 219.5; 
P = 0.01) treatments (Figure 2E and 2F). Patients with 
Positive-sHGF at diagnosis (pre-treatment of first-line) 
did not have significantly shorter PFS compared with 
patients with Negative-sHGF (P = 0.82) (Supplementary 
Figure 3C and 3D). In second-line treatment, the number 
of patients receiving EGFR-TKI was larger for Negative-
sHGF compared with Positive-sHGF (Table 2). Subgroup 
analyses in both patients receiving EGFR-TKI and CC 
in second-line treatment showed that in both subgroups 
patients with Positive-HGF tended to have shorter PFS 
(Supplementary Figure 4).
sHGF was a predictive factor for PFS in patients 
that received cytotoxic chemotherapy
Next, clinical impact of sHGF in patients that 
received CC was investigated. In this retrospective 
cohort, fifty-five patients received CC. Cox proportional 
hazards models showed univariate associations (P < 0.2) 
between poor PFS and five factors; Positive-sHGF at 
response-evaluation, ECOG performance status (PS), 
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EGFR-WT (or squamous cell carcinoma), second-
line treatment, and monotherapy. A multivariate Cox 
proportional hazards model that included the five factors 
suggested that monotherapy and performance status were 
no longer significant factors (Supplementary Table 1). 
Monotherapy was highly correlated with second-line 
therapy (P < 0.01, Fisher’s exact test, Supplementary 
Table 2). Then, the other four factors (sHGF, EGFR-WT, 
ECOG-PS, and second-line treatment) were included 
for the final multivariate Cox analysis, which detected a 
continued significant independent association between 
poor PFS and the sHGF value at response-evaluation 
(hazard ratio, 4.24; 95% CI, 2.00 to 9.25; P < 0.01) 
(Table 3). The backgrounds of the patients are presented 
in Supplementary Table 2.
sHGF was a potential predictive factor for PFS 
in patients after cytotoxic chemotherapy
Then, the clinical significance of sHGF in second-
line treatment after the first-line CC was investigated. 
Thirty patients subsequently received second-line 
treatment after progression in first-line CC (Supplementary 
Table 3). Positive-sHGF after first-line cytotoxic 
Figure 1: sHGF values in patients with NSCLC. (A) sHGF values in healthy controls and patients with NSCLC. In healthy controls, 
values under the limit of detection (0.3 ng/ml) were extrapolated using a calibration curve. (B, C) The change in sHGF values in patients 
with NSCLC receiving first-line treatment (B) and second-line treatment (C). Black dots show the concentration of sHGF at 4 time points 
during treatment. sHGF medians, the rates of Positive-sHGF at each time point (positive rate), and the objective response at each time point 
are indicated below. In all Figures, the Mann-Whitney U test was used for comparisons.
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chemotherapy (pretreatment of second-line therapy) 
predicted poorer PFS in second-line therapy compared 
with Negative-sHGF (median PFS, 98.0 vs. 215.0 days; 
HR, 2.05; P = 0.03 (logrank test), Figure 3A)
sHGF was a predictive factor for PFS in patients 
with lung adenocarcinoma receiving cytotoxic 
chemotherapy
Finally, PFS in patients with lung adenocarcinoma 
treated with CC was examined by using sHGF values 
and a control marker, CEA. There were no significant 
differences in PFS or HR between patients with high-
CEA compared with low-CEA at any time-points during 
the treatment course (Figure 3D, Supplementary Figure 5). 
In contrast, Positive-sHGF in patients receiving second 
CC predicted poorer PFS compared with Negative-sHGF 
both at pretreatment (median PFS, 35.0 vs. 132.0 days; 
HR, 4.55; P = 0.01, Figure 3B and 3D), and at response-
evaluation (median PFS, 50.0 vs. 215.0 days; HR, 14.3; 
P < 0.01, Figure 3C and 3D). In first CC, Positive-sHGF 
at response-evaluation tended to predict shorter PFS, but a 
significant difference was not detected (median PFS, 163.0 
vs. 281.5 days, P = 0.11). (Supplementary Figure 6)
DISCUSSION
Here we reported that sHGF was associated with 
tumor response. Positive-sHGF at response-evaluation 
and at pre-treatment of the second CC also predicted poor 
PFS.
To date, the relationship between circulating HGF 
and clinical outcome has been reported in NSCLC. In 
early stage NSCLCs, sHGF was significantly higher 
compared with healthy controls [27] and predicted early 
recurrence after a standard operation [28, 29]. In patients 
treated with EGFR-TKIs, high circulating HGF predicted 
poor prognosis [30–33]. To the best of our knowledge, 
this is the first report to suggest the merit of sHGF as a 
potential biomarker in patients with advanced or recurrent 
NSCLC including populations receiving CC.
This trend of sHGF was concordant with the 
treatment effect (Figure 1B and 1C). Correspondingly, 
previous reports showed that the circulating HGF value 
was decreased after tumor resection in lung and breast 
cancer [18, 28], and was parallel with tumor response in 
SCLC [25]. sHGF protein is a tumor volume marker in 
patients with advanced or recurrent NSCLC. However, 
sHGF in patients with PD was not increased at response-
evaluation and tended to be increased before the next 
treatment regimen, which suggested that the sHGF value 
was not just a volume marker.
Positive-sHGF at response-evaluation predicted 
early disease progression, but Positive-HGF at 
diagnosis did not. Similarly, previous reports showed 
that immunohistochemical overexpression of c-MET or 
high sHGF at diagnosis was not a prognostic factor in 
patients with NSCLC [31, 34]. As sHGF values correlate 
with tumor volume, the values at diagnosis would not 
predict early progression. In the current study, sHGF 
was potentially useful to predict PFS at a later time-point 
of the treatment course, although serum CEA was not 
(Figure 3C). It should be noted that Positive-sHGF can 
potentially identify treatment refractory patients at the 
start of the second CC. The sHGF value was not just a 
volume marker, but potentially predicted drug resistance.
Preclinical studies have explained the mechanism 
for increased sHGF in patients with poor PFS. HGF 
is a paracrine protein secreted by mesenchymal cells 
regulating cellular growth, motility, and morphogenesis, 
that acts as a multifunctional cytokine mainly in 
epithelial-origin cells [35]. Activation of HGF/MET 
autocrine in HGF- or MET-transgenic mice in vivo 
promoted hepatocarcinogenesis [36, 37]. We previously 
provided preclinical evidence that cytotoxic drug-
resistant lung cancer cells secreted HGF and accelerated 
its resistance by increased expression of c-MET due to 
gene amplification, and that c-Met inhibitors restored 
cytotoxic drug sensitivity [26, 38]. A high sHGF value 
at later time-points of the treatment course would be 
associated with activity in the HGF/c-MET signaling 
pathway in the tumor.












N 30 53 48
Sex Female 16 (46.7%) 24 (45.3%) 0.48 21 (43.8%) 0.41
Age yr. (mean ± S.D.) 63.8 ± 7.0 65.6 ± 9.3 0.42 64.5 ± 11.8 0.85
Smoking Never 11 (36.7%) 22 (41.5%) 0.66 21 (43.8%) 0.54
 Smoker 19 (73.3%) 31 (58.5%) 27 (56.3%)
The characteristics of the healthy volunteers in this study. Data are presented as numbers. P-values were calculated using 
the chi-square test or Student’s t-test in categorical variables or continuous variables, respectively. NSCLC: non-small cell 
lung cancer; pts: patients.
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For the clinical use of sHGF, it should serve as a 
marker for HGF/cMET activity. Companion diagnostics 
for MET inhibitors are needed, because a phase III 
trial failed to demonstrate that adding Onartuzumab, a 
MET inhibitor, to erlotinib improves overall survival in 
patients with NSCLC, although phase II and preclinical 
studies have suggest promising effects [39–42]. To date, 
immunohistochemistry of c-MET or genetic tests of 
Figure 2: sHGF levels at response-evaluation predict progression-free survival. (A, B) sHGF values according to the best 
response in patients that received first-line (A) and second-line (B) therapy. The P-value was calculated using the Mann-Whitney U test. (C, 
D) Serum hepatocyte growth factor (sHGF) levels at response-evaluation according to the achieved best response in first-line treatment (C) 
and second-line treatment (D). Red or blue dots indicate the sHGF value in each group and the bars show the median value. The P-value 
was calculated using the Mann-Whitney U test. (E, F) A Kaplan-Meier curve for progression-free survival according to sHGF levels at 
response-evaluation in patients with NSCLC receiving first-line treatment (E) and second-line treatment (F). The P-value was calculated 
using the Gehan-Breslow-Wilcoxon test. DC: disease control; PD: progressive disease; LOD: limit of detection.
Oncotarget71810www.impactjournals.com/oncotarget
MET have been used to evaluate HGF-c-MET activity 
[43]. However, there are several problems with these 
methods; repeated biopsy or frequent monitoring are 
complicated, small biopsy specimens from one lesion may 
not detect dominant resistant mechanisms in the whole 
tumor [44], and there are few chances to perform a re-
biopsy in patients receiving CC. sHGF values are easy to 
monitor and suitable for determining dominant molecular 
alterations in the whole tumor. We hypothesize that the 
sHGF value could be used as a simple and repeatable 
activity marker for the HGF/c-MET pathway and provide 
a supplemental marker to indicate re-biopsy demonstrating 
HGF/c-MET activation.
A limitation of this study is its retrospective design 
and small sample size. Unexpected confounding biases 
and the influence of data deficiency cannot be excluded. 
Due to the supportive results in univariate and multivariate 
analyses, we believe that any bias would not influence our 
findings. Another limitation is that the correlation between 
sHGF values and c-MET activation was not investigated 
because re-biopsy for patients treated with CC is unusual. 
In future, activation of c-MET in patients treated with 
CC and showing a high sHGF value may merit further 
prospective investigation. Finally, at present, there is no 
conventional threshold for Positive-sHGF concentrations 
in patients with NSCLC. In previous studies, the threshold 
Table 2: Patients’ characteristics in the current study
















N 53 25 16 48 24 16
Gender Female 24 (45.3%) 14 (56.0%) 5 (31.3%) 0.20 21 (43.8%) 11 (45.8%) 8 (50.0%) 0.77 
Age yr. (mean ± S.D.) 65.6 ± 9.3 64.8 ± 9.6 64.3 ± 9.6 0.88 64.5 ± 11.8 66.5 ± 11.2 59.1 ± 12.1 0.06
PS ≥ 2 6 (11.3%) 3 (12.0%) 1 (6.3%) 1.00 5 (10.4%) 2 (8.3%) 2 (12.5%) 1.00 
 0–1 47 (88.7%) 22 (88.0%) 15 (93.8%) 43 (89.6%) 22 (91.7%) 14 (87.5%)
Smoking Never 22 (41.5%) 9 (36.0%) 6 (37.5%) 1.00 21 (43.8%) 15 (62.5%) 5 (31.3%) 0.11 
 Smoker 31 (58.5%) 16 (64.0%) 10 (62.5%) 27 (56.3%) 9 (37.5%) 11 (68.8%)
Histology Ad 39 (73.6%) 20 (80%) 8 (50.0%) 0.11 41 (85.4%) 20 (83.3%) 13 (81.3%) 0.67 
 Sq 10 (18.9%) 3 (12.0%) 6 (37.5%) 3 (6.3%) 2 (8.3%) 1 (6.3%)
 Others 4 (7.6%) 2 (8.0%) 2 (12.5%) 4 (8.4%) 2 (8.3%) 2 (12.5%)
EGFR 
mutation
Positive 23 (43.4%) 10 (40.0%) 5 (31.3%) 0.51 23 (47.9%) 15 (62.5%) 6 (37.5%) 0.19 
Wild type 26 (49.1%) 12 (48.0%) 10 (62.5%) 23 (47.9%) 8 (33.3%) 10 (62.5%)
 Unknown 4 (7.6%) 3 (12.0%) 1 (6.3%) 2 (4.2%) 1 (4.2%) 0 (0%)
Stage IIIA 0 (0%) 0 (0%) 0 (0%) 3 (6.3%) 2 (8.3%) 1 (6.3%)
 IIIB 4 (7.6%) 3 (12.0%) 0 (0%) 4 (8.3%) 1 (4.2%) 1 (6.3%)
 IV 42 (79.3%) 17 (68.0%) 16 (100%) 35 (72.9%) 18 (75%) 12 (75.0%)
 Recurrence 7 (13.2%) 5 (20%) 0 (0%) 6 (12.5%) 3 (12.5%) 2 (12.5%)
Treatment CC 36 (67.9%) 18 (72.0%) 13 (81.3%) 0.71 31 (64.6%) 11 (45.8%) 13 (81.3%) *0.05
 EGFR-TKI 17 (32.1%) 7 (28.0%) 3 (18.8%) 17 (35.4%) 13 (54.2%) 3 (18.8%)
Response CR 1 (1.9%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 PR 29 (54.7%) 13 (52.0%) 7 (43.8%) 11 (22.9%) 8 (33.3%) 1 (6.3%)
 SD 14 (26.4%) 9 (36.0%) 3 (18.8%) 22 (45.8%) 12 (50.0%) 5 (31.3%)




56.6/83.0% 52.0/88.0% 43.8/62.5% 22.9/68.8% 33.3/83.3% 6.3/37.6%
The characteristics of the patients with Positive-HGF and Negative-HGF at response-evaluation who received first-line or 
second-line therapy in this study. Data are presented as numbers. P-values were calculated using the Fisher’s exact test or 
chi-square test, as appropriate, comparing Positive- and Negative-HGF patients. RE: response-evaluation; PS: performance 
status; Ad: adenocarcinoma; Sq: squamous cell carcinoma; LCC: large cell carcinoma; NSCLC: non-small cell carcinoma; 
EGFR: epidermal growth factor receptor; CC: cytotoxic chemotherapy; TKI: tyrosine kinase inhibitor; CR: complete 
response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease 
control rate.
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values for Positive-sHGF were approximately 1.9 ng/ml in 
SCLC [25], 2.4 ng/ml in gastric cancer [15], and 0.4 ng/
ml in bladder cancer [45]. Mean sHGF values in healthy 
controls in previous reports also vary considerably (0.08 
to 1.37 ng/ml) [25, 45–47]. In the current study, we used 
an ELISA kit which had been designed and approved for 
clinical use. The sHGF value in 200 Japanese healthy 
controls was reported as 0.19 ± 0.05 ng/ml (mean ± S.D.)
[45]. According to historical controls of this kit and our 
healthy control study, the cutoff value was equivalent 
with an average +1.6 to +2.2 S.D. in healthy controls. 
The threshold might be different among tumor origins, 
histology, and the ELISA procedures. We believe that a 
standardized procedure and sharing of cutoff values is 
needed between clinics and translational laboratories.
In conclusion, the current study provided the 
first evidence that sHGF values were associated with 
the treatment response, and that the values at response-
evaluation and at pre-treatment of the second CC are 
predictive markers of poor PFS in patients with NSCLC. 
Figure 3: sHGF levels at a later time-phase predict progression-free survival in patients that received cytotoxic 
chemotherapy. (A) A Kaplan-Meier curve for progression-free survival according to sHGF levels in patients that received second-line 
treatment after progression during first-line cytotoxic chemotherapy. The P-value was calculated using the Gehan-Breslow-Wilcoxon test. 
(B, C) A Kaplan-Meier curve for progression-free survival according to sHGF levels at pre-treatment (B) and at response-evaluation (C) 
in patients with lung adenocarcinoma receiving second cytotoxic chemotherapy. The P-value was calculated using the Gehan-Breslow-
Wilcoxon test. (D) The hazard ratios (HR) for progression (black squares) and 95% CIs (horizontal lines). The HRs and P-values were 
calculated using the logrank test. The patients’ characteristics are presented in Supplementary Tables 4 and 5. HGF: hepatocyte growth 
factor; PFS: progression-free survival; 95% CI: 95 percent confidential interval; CC: cytotoxic chemotherapy; CEA: carcinoembryonic 
antigen.
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These findings suggest future research investigating the 
merit of sHGF as a potential clinical biomarker to indicate 
administration of MET inhibitors in patients with NSCLC, 
or as a re-biopsy marker for patients treated with CC, 
may lead to the development of a new indicator of MET 
inhibitors and improve targeted therapies for lung cancer.
MATERIALS AND METHODS
Patients and clinical information
Between November 2013 and December 2015, 
serum samples from 81 patients with advanced cancer 
or receiving anticancer treatment were collected and 
cryopreserved at Kyoto University Hospital (Kyoto, 
Japan). Patients who were not evaluated objective 
response were excluded. Clinical information was 
obtained from electronic medical records at the institution. 
The study protocol had been prepared in accordance 
with the Declaration of Helsinki and was approved by 
the Kyoto University Graduate School and Faculty of 
Medicine Ethics Committee. All patients provided written 
informed consent for clinical investigation.
Measurement and assessment of sHGF and 
carcinoembryonic antigen (CEA)
Serum was immediately separated from blood 
samples by centrifugation at 4°C and cryopreserved at 
−80°C until assays were performed. sHGF levels were 
measured at a medical laboratory testing company, SRL 
(Tokyo, Japan), using an enzyme-linked immunosorbent 
assay (ELISA) kit (Otsuka Pharmaceutical, Tokyo, Japan), 
which was designed and approved for use in diagnostic 
procedures. The mean ± S.D. level of sHGF in 200 adult 
Japanese healthy controls was 0.19 ± 0.05 ng/ml and the 
lower limit of detection had been determined to be 0.3 
ng/ml, according to the manufacturer’s data sheet [45]. 
sHGF values were categorized into 4 subgroups by time-
points during the treatment; at pre-treatment, at response-
evaluation (1–2 months after treatment initiation), at best 
tumor response, and at disease progression based on the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria ver. 1.1 [48]. As a control biomarker, the levels of 
serum CEA were also evaluated using ELISA. The values 
for sHGF were classified into 2 categories, Negative-sHGF 
and Positive-sHGF, with a threshold of 0.3 ng/ml since 
this is the lower limit of detection. The control biomarker, 
serum high-CEA, was defined in each subgroup as more 
than the median value of categorized subjects. First-line, 
second-line, first CC, and second CC treatments were 
defined in the conventional way (Supplementary Figure 1). 
sHGF in healthy control
The blood samples of healthy controls had been 
obtained in Kyoto University Hospital from August 
2012 to December 2015 from volunteers without 
history of malignancy or hepatic disease. The serum 
was immediately separated and cryopreserved at −80°C 
without any freeze-thaw cycle until the assay was 
conducted. From the serum library, 30 healthy controls 
that were matched to the current study population by 
smoking status, gender, and age were collected. The 
sHGF value was evaluated using the same procedure as 
used for patients with NSCLC. Written informed consent 
Table 3: Univariate and multivariate analysis in patients that received cytotoxic chemotherapy 
using Cox proportional hazards model
N=55 Univariate analysis Multivariate analysis
Factor HR (95% CI) P-value HR (95% CI) P-value
Gender (Male / Female) 0.9 (0.51–1.63) 0.73
Age yr (≥ 65 / < 65) 0.82 (0.47–1.46) 0.51
Smoking (Smoker / Never Smoker) 1.2 (0.67–2.21) 0.55
ECOG-PS (PS ≥ 2 / PS 0–1) 4.12 (0.94–12.84) *0.06 > 1.45 (0.32–4.85) 0.59
Stage (IV / recurrence / III) 0.6 (0.28–1.59) 0.28
Histology (Non-ad / Ad) 1.48 (0.8–2.64) 0.21
EGFR-status (Negative or Sq / mutant) 2.3 (1.09–5.66) *0.03 > 5.96 (2.29–17.85) *< 0.01
Monotherapy (Monotherapy / Platinum Doublet) 2.06 (1.09–3.78) *0.03
Second-line (2nd-line / 1st-line) 2.01 (1.12–3.63) *0.02 > 2.11 (1.14–3.94) *0.02
sHGF at pre-treatment (Positive / Negative) 1.25 (0.68–2.26) 0.45
sHGF at response-evaluation (Positive / Negative) 2.1 (1.18–3.73) *0.01 > 4.24 (2–9.25) *< 0.01
HR: hazard ratio; ECOG: Eastern Cooperative Oncology Group; PS: performance status; Ad: adenocarcinoma; EGFR: 
epidermal growth factor receptor; Sq: squamous cell carcinoma.
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had been obtained from these healthy controls at the time 
of blood sampling, and supplemental informed consent 
was obtained for using the serum in the current study. 
This healthy control study was also approved by the 
institutional ethics committee.
Subgroup analysis
To assess the trend of sHGF values in the treatment 
course and the association between sHGF and clinical 
outcome, all patients were included for analysis. To 
assess the clinical predictive value of sHGF with CEA, 
patients with lung adenocarcinoma were exclusively 
included, because CEA, the control tumor marker, is a 
marker for adenocarcinoma, but not for other histology 
types in lung cancer.
Statistical analysis
The efficacy was determined using the objective 
response rate (ORR), disease control rate (DCR), and PFS, in 
accordance with the RECIST criteria [48]. Differences in the 
distribution of variables were evaluated using Fisher’s exact 
test or the chi-square test, as appropriate. sHGF values were 
not continuous variables and the difference was evaluated 
using the Wilcoxon matched-pairs signed rank test or the 
Mann-Whitney U test, as appropriate. PFS were estimated 
using the Kaplan–Meier Method, and survival curves were 
compared using the Gehan-Breslow-Wilcoxon or logrank 
test. Hazard ratios (HRs) and the corresponding 95% 
confidence intervals (CIs) for PFS were calculated using 
univariate analysis by the Cox proportional hazards model. 
In patients receiving cytotoxic chemotherapy, univariate 
Cox proportional hazards models were used to evaluate 
the associations between PFS and patient characteristics 
as follows; gender, age, smoking, ECOG performance 
status, stage, histology, EGFR-status, monotherapy, second-
line treatment, and the sHGF value. Variables showing a 
univariate association with PFS (at P < 0.20) were included 
in stepwise multivariate Cox proportional hazards models. 
All tests were 2-sided, and a P-value of 0.05 was defined 
as significant. All statistical analyses were performed using 
JMP Pro version 12.0 (SAS Institute, Inc., Cary, NC, United 
States) and visualized by GraphPad Prism 6 (GraphPad 
software, La Jolla, CA, United States).
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